Literature DB >> 35125692

Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.

Bijo Varughese1, Dnyanoba Madrewar2, Sunil Kumar Polipalli1, Seema Kapoor1.   

Abstract

Tyrosinemia type 1 (TYR1) is a devastating aminoacidopathy, leading to mortality without medical intervention. Although, detection and quantification of tyrosine in dried blood spot (DBS) is possible, but being a non-specific marker for TYR1 and its frequent association with transient neonatal tyrosinemia limits its applicability. Despite, Succinylacetone (SUAC) being a pathognomonic marker for TYR1, but not often detectable by routine newborn screening (NBS). We envisaged to determine SUAC in DBS by an in-house flow injection analysis method on a liquid chromatography/tandem mass spectrometry (LC-MS/MS). Succinylacetone was eluted from the residual 3.2 mm DBS of primary NBS by an extraction solution containing acetonitrile-water-formic acid mixture containing stable-isotope labelled internal standard (IS) for SUAC and hydrazine. Detection and quantification was performed by the mass spectrometer using multiple reaction monitoring mode at m/z 155.1 → 109.1 for SUAC and m/z 160.1 → 114.1 for the SUAC IS. The assay was linear over a calibration range of 0.122-117.434 µmol/L. The Intra-day and Inter-day precision and accuracy for the assay was determined at two different levels of SUAC (2.542 µmol/L and 14.641 µmol/L), which showed a coefficient of variation of (6.91% and 12.65%) and (8.57% and 12.27%) respectively. The accuracy also ranged between 101.2 and 103.87%.This method provided the necessary sensitivity, precision, accuracy, recovery and linearity and hence, has the potential to reduce the false positive, false negative results which significantly minimise the cost involved in the screening and follow up of TYR1 patients. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s12291-020-00944-z) contains supplementary material, which is available to authorized users. © Association of Clinical Biochemists of India 2021.

Entities:  

Keywords:  Fumarylacetoacetate hydrolase; Inborn errors of metabolism; Mass spectrometry; Newborn screening; Tyrosine; Tyrosinemia type 1

Year:  2021        PMID: 35125692      PMCID: PMC8799791          DOI: 10.1007/s12291-020-00944-z

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  42 in total

1.  Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.

Authors:  Víctor R De Jesús; Barbara W Adam; Daniel Mandel; Carla D Cuthbert; Dietrich Matern
Journal:  Mol Genet Metab       Date:  2014-07-17       Impact factor: 4.797

Review 2.  Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing.

Authors:  Mohammed Almannai; Ronit Marom; V Reid Sutton
Journal:  Curr Opin Pediatr       Date:  2016-12       Impact factor: 2.856

3.  Transient tyrosinemia in full-term infants.

Authors:  H L Levy; V E Shih; P M Madigan; R A MacCready
Journal:  JAMA       Date:  1969-07-14       Impact factor: 56.272

4.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

5.  Aminoacidopathies and organic acidurias in Tunisia: a retrospective survey over 23 years.

Authors:  Sameh Hadj-Taieb; Fehmi Nasrallah; Mohamed B Hammami; Monia Elasmi; Haifa Sanhaji; Feki Moncef; Naziha Kaabachi
Journal:  Tunis Med       Date:  2012-03

6.  Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.

Authors:  R Berger; G P Smit; S A Stoker-de Vries; M Duran; D Ketting; S K Wadman
Journal:  Clin Chim Acta       Date:  1981-07-18       Impact factor: 3.786

7.  Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.

Authors:  Coleman Turgeon; Mark J Magera; Pierre Allard; Silvia Tortorelli; Dimitar Gavrilov; Devin Oglesbee; Kimiyo Raymond; Piero Rinaldo; Dietrich Matern
Journal:  Clin Chem       Date:  2008-02-15       Impact factor: 8.327

8.  Prenatal diagnosis of hereditary tyrosinaemia: measurement of succinylacetone in amniotic fluid.

Authors:  R Gagné; A Lescault; A Grenier; C Laberge; S B Mélançon; L Dallaire
Journal:  Prenat Diagn       Date:  1982-07       Impact factor: 3.050

Review 9.  Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.

Authors:  Chris Stinton; Julia Geppert; Karoline Freeman; Aileen Clarke; Samantha Johnson; Hannah Fraser; Paul Sutcliffe; Sian Taylor-Phillips
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

Review 10.  Recommendations for the management of tyrosinaemia type 1.

Authors:  Corinne de Laet; Carlo Dionisi-Vici; James V Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; Hélène Ogier de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter
Journal:  Orphanet J Rare Dis       Date:  2013-01-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.